Agomelatine: a review for general practitioners

References

• The global burden of disease. 2004 update. Geneva: World Health Organization: 2008 [homepage on the Internet]. c2011. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
   Google Scholar
• Tomlinson M, Grimsrud AT, Stein DJ, et al. The epidemiology of major depression in South Africa: results from the South African Stress and Health study. S Afr Med J. 2009; 99(5 Pt 2): 368–373.
   Web of Science ®Google Scholar
• Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965; 122(5): 509–522.
   PubMed Web of Science ®Google Scholar
• Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: Implications for the etiology and therapy of depression. Arch Gen Psychiatry. 1981; 38(10): 1160–1180.
   PubMed Web of Science ®Google Scholar
• Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organisation and coordination of central and peripheral clocks. Annu Rev Physiol. 2010; 72: 517–549.
   PubMed Web of Science ®Google Scholar
• De Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010; 9(8): 628–642.
   PubMed Web of Science ®Google Scholar
• Kennaway DJ, Moyer RW, Voultsios A, Varcoe TJ. Serotonin, excitatory amino acids and the photic control of melatonin rhythms and SCN c-FOS in the rat. Brain Res. 2001; 897(1–2): 36–43.
   PubMed Web of Science ®Google Scholar
• Hajak G, Landgrebe M. Time and depression. When the internal clock does not work. Medicographica. 2010; 32: 146–151.
   Google Scholar
• Dalton EJ, Rotondi D, Levitan RD, et al. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci. 2000; 25(1): 48–52.
   PubMed Web of Science ®Google Scholar
• San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008; 23(6): 396–402.
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010; 25(2): 95–102.
   PubMed Web of Science ®Google Scholar
• Valdoxan. Summary of product characteristics. eMC [homepage on the Internet]. c2011. Available from: http://www.medicines.org.uk/emc/medicine/21830/SPC/
   Google Scholar
• Howland RH. A risk-benefit assessment of agomelatine in the treatment of depression. Drug Saf. 2011; 34(9): 709–731.
   PubMed Web of Science ®Google Scholar
• Loo H, Dale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT (2C) antagonist, in the treatment of major depressive disorder: a placebo controlled dose range study. Int Clin Psychopharmacol. 2002; 17(5): 1723–1732.
   Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006; 16(2): 93–100.
   PubMed Web of Science ®Google Scholar
• Olie JP Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007; 10(5): 661–673.
   Google Scholar
• Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol. 2007; 22(5): 283–291.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: An 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010; 71(5): 616–626.
   PubMed Web of Science ®Google Scholar
• Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicentre, randomized, double-blind, placebo controlled trial. J Clin Psychopharmacol. 2010; 30(2): 135–144.
   PubMed Web of Science ®Google Scholar
• Kasper S. Effect of agomelatine on rest-activity cycle in patients with major depressive disorder compared to sertraline. Int J Neuropsychopharmacol. 2008; 11(1): 193.
   Google Scholar
• Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010; 71(2): 109–120.
   PubMed Web of Science ®Google Scholar
• Lemoine P Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomised, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007; 68(11): 1723–1732.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008; 28(3): 329–333.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004; 19(5): 271–280.
   PubMed Web of Science ®Google Scholar
• Hale A, Corral R, Mencacci O, et al. Superior efficacy of agomelatine vs fluoxetine in severe MDD patients: a randomised, double-blind study. J Eur College of Neuropsychopharmacology. 2009; 19(Suppl 3):S418.
   Google Scholar
• Goodwin GM, Elmsey R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(8): 1128–1137.
   PubMed Web of Science ®Google Scholar
• Quera Salva MA, Hajak G, Philip P, et al Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacology. 2011; 26(5): 252–262.
   PubMed Web of Science ®Google Scholar
• Cajochen C, Kräuchi K, Möri D, et al. Melatonin and S20098 increase REM and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol. 1997; 272(4 Pt 2): R1189–R1196.
   PubMed Web of Science ®Google Scholar
• Kräuchi K, Cajochen C, Möri D, et al. Early evening melatonin and S20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol. 1997; 272(4 Pt 2): R1178–R1188.
   PubMed Web of Science ®Google Scholar
• Lopes MC, Quera-Salva MA, Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med. 2007; 9(1): 33–41.
   PubMed Web of Science ®Google Scholar
• Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open label study. Int J Neuropsychopharmacol. 2007; 10(5): 691–696.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms within depression. European Neuropsychopharmacology. 2011; 21(Supplement 3): S383.
   Google Scholar
• Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalised anxiety disorder: a randomized, double blind, placebo controlled study. J Clin Psychopharmacol. 2008; 28(5): 561–566.
   PubMed Web of Science ®Google Scholar
• Marqués Cabezas P, Cabus Piñol G, Coullaut-Valera García J, et al. Agomelatine in the treatment of obsessive-compulsive-disorder: potential for clinical effectiveness: a 4-week, multicenter, randomized, placebo-controlled trial. Euro Psychiatry. 2011; 26(Supplement 1):974.
   Google Scholar
• Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann Gen Psychiatry. 2011; 10(1): 5.
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl). 2007; 190(4): 575–579.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Guelfi JD, Perdrizet-Chevallier C, Agomelatine Bipolar Study Group. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007; 9(6): 628–635.
   PubMed Web of Science ®Google Scholar
• Anderson G. Melatonin, agomelatine and alcoholism: relevance to alcohol-related brain damage and comorbid psychosis. Addict Disord Their Treatment. 2011; 10: 84–90.
   Google Scholar
• Niederhofer H. Efficacy of duloxetine and agomelatine does not exceed that of other antidepressants in patients with autistic disorder: preliminary results in 3 patients. Prim Care Companion CNS Disord. 2011; 13(1): pii: PCC.10l01038.
   Google Scholar
• Müller H, Schü&tz P, Maler JM, Kornhuber J. Agomelatine as adjunctive therapy in discontinuation of long-term benzodiazepine withdrawal. European Psychiatry. 2011; 26(Suppl 1):87.
   Google Scholar
• Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol. 2010; 24(1): 111–120.
   Google Scholar
• Haddad PM, Anderson I. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat. 2007; 13: 447–457.
   Google Scholar